JP Morgan Chase
ENTA icon

JP Morgan Chase’s Enanta Pharmaceuticals ENTA Stock Holding History

JP Morgan Chase’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-27,000
Closed -$2.31M – 5737
2018
Q3 		$2.31M Sell
27,000
-3,000
-10% -$301K ﹤0.01% 3358
2018
Q2 		$3.48M Buy
+30,000
New +$2.99M ﹤0.01% 2975

Other funds holding ENTA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase's ENTA Position: Q2 2026 in Review

JP Morgan Chase reduced its Enanta Pharmaceuticals (ENTA) stake by 6.1% in Q2 2026, selling an estimated $84.6K and leaving 96,764 shares worth $1.4M. The position accounts for ﹤0.01% of the portfolio, ranked #4444.

JP Morgan Chase first reported a position in ENTA in Q1 2015 and has held it in 43 quarters since. The position peaked at $9.76M in Q4 2017. 123 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

  • JP Morgan Chase held 96,764 shares of Enanta Pharmaceuticals worth $1.4M as of Q2 2026.
  • JP Morgan Chase sold 6,295 Enanta Pharmaceuticals shares in Q2 2026, an estimated $84.6K.
  • Enanta Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #4444 holding.
  • JP Morgan Chase first reported a position in Enanta Pharmaceuticals in Q1 2015 and has held it in 43 quarters since.
  • JP Morgan Chase's Enanta Pharmaceuticals position peaked at $9.76M in Q4 2017.
  • 123 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.